- Global Pharma News & Resources

Evofem Biosciences to Report Fourth Quarter and Year-end 2018 Results and Provide Corporate Update on March 1, 2019

SAN DIEGO, Feb. 19, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2018, as follows:


Friday March 1, 2019


11:00 a.m. EST

Dial-in numbers

(866) 503-5561 (U.S. toll-free) or (253) 336-2965



Webcast (live and archived) under "Investors" or click here

The teleconference replay will be available approximately two hours after completion through Wednesday, March 6, 2019, at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The replay access code is 5892398. The archived webcast will be available via the aforementioned URLs. 

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs). The Company is leveraging its proprietary Multi-purpose Vaginal pH Regulator™ (MVP-R) platform to develop Amphora which, if approved, will be the first on-demand and female controlled MVP-R birth control method in the U.S. For more information regarding Evofem, please visit

Amphora® is a registered trademark and Multipurpose Vaginal pH Regulator™ is a trademark of Evofem Biosciences, Inc.

Amy Raskopf
Evofem Biosciences, Inc.
C: (917) 673-5775
O: (858) 550-1900 x167


View original content to download multimedia:

SOURCE Evofem Biosciences, Inc.

Editor Details

Last Updated: 19-Feb-2019